Clinical response among golimumab-treated Japanese patients with rheumatoid arthritis by number of previous biologic therapies: Real-world evidence from post-hoc analysis of post-marketing surveillance data

Abstract

Clinical response among golimumab-treated Japanese patients with rheumatoid arthritis by number of previous biologic therapies: Real-world evidence from post-hoc analysis of postmarketing surveillance data, Modern Rheumatology,

Predictive factors for retention of golimumab over a median 4‐year duration in Japanese patients with rheumatoid arthritis in a real‐world setting: A retrospective study and literature review

“…Two cohort studies demonstrated no significant difference in persistence of GLM between biologics-naïve and biologics-experienced patients at 2 11 and 5 15 years, respectively, whereas, 3 registries from European countries have reported an increase in retention rates at 2, 17 5, 23 and 7 18 years, when GLM was used as the first-line biological therapy. Although our results are consistent with the findings of PMS 27,31 and several registries except for Japan, 17,18,23 further studies are necessary to validate these findings, particularly by including greater number of Japanese patients with longer observational periods.…”

“…27 Additionally, further data from PMS in recent years have demonstrated that switching to GLM was effective despite the number of previously used biologics, but clinical response declined with an increasing number of prior biological therapies. 31 However, there has been limited evidence on long-term retention rates stratified by the number of prior biological therapies in routine practice. Two cohort studies demonstrated no significant difference in persistence of GLM between biologics-naïve and biologics-experienced patients at 2 11 and 5 15 years, respectively, whereas, 3 registries from European countries have reported an increase in retention rates at 2, 17 5, 23 and 7 18 years, when GLM was used as the first-line biological therapy.…”

Predicting the clinical efficacy of JAK inhibitor treatment for patients with rheumatoid arthritis based on Fas+ T cell subsets

“…The responses to medication were classified in accordance with EULAR response criteria (Supplementary data S1). A good response (GR) was defined as DAS28‐ESR ≤3.2 with a decrease of >1.2 by 6 m. A moderate response (MR) was defined as DAS28‐ESR ≤3.2 with a decrease of >0.6 and ≤1.2 by 6 m, or DAS28‐ESR ≤5.1 and >3.2 with a decrease of >0.6 by 6 m, or DAS28‐ESR >5.1 with a decrease of >1.2 by 6 m. Non‐response (NR) was defined as DAS28‐ESR >5.1 with a decrease of >0.6 and ≤1.2 by 6 m, or a decrease of ≤0.6 by 6 m [7].…”